Table 2 Univariate and multivariate analysis of progression-free survival
Clinical parameter | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
n (% ) | Median (months) | P value | HR (95% CI) | P value | |
Age | |||||
< 65 | 38 (82, 6%) | 14, 1 | 0, 076 | NS | NS |
≥ 65 | 8 (17, 4%) | 23, 2 | |||
Histopathologic cell type | |||||
Serous | 24 (52, 2%) | 13, 8 | 0, 028 | NS | NS |
Others | 22 (47, 8%) | 23, 2 | |||
Residual tumor size | |||||
<1 cm | 19 (41, 3%) | 21, 8 | 0, 054 | NS | NS |
> 1 cm | 27 (58, 7%) | 10, 7 | |||
Performance status (ECOG) | |||||
0-1 | 43 (93, 5%) | 16, 7 | 0, 564 | ||
2 | 3 (6, 5%) | 22, 0 | |||
Tumor grade | |||||
G1, G2 | 21 (45, 6%) | 12, 9 | 0, 981 | ||
G3, unknown | 25 (54, 4%) | 17, 5 | |||
E-cadherin membranous | |||||
Negative | 7 (15, 2%) | 16, 7 | 0, 775 | ||
Positive | 39 (84, 8%) | 15, 9 | |||
E-cadherin cytoplasmic | |||||
Negative | 1 (2, 2%) | ||||
Positive | 45 (97, 8%) | - | - | ||
β-catenin membranous | |||||
Normal | 21 (45, 6%) | 9, 9 | 0, 024 | 2, 19 (1, 09-4, 39) | 0, 028 |
Decreased | 25 (54, 4%) | 22, 8 | |||
β-catenin cytoplasmic | |||||
Negative | 27 (58, 7%) | 15, 4 | 0, 806 | ||
Positive | 19 (41, 3%) | 16, 7 | |||
β-catenin nuclear | |||||
Negative | 46 (100, 0%) | - | - | ||
Positive | 0 (0, 0%) | ||||
WNT-1 | |||||
Normal | 31 (67, 4%) | 13, 5 | 0, 898 | ||
Decreased | 15 (32, 6%) | 18, 8 | |||